IO Biotech CEO Mai-Britt Zocca discusses the phase 3 pivotal trial result of the cancer vaccine Cylembio in first line advanced melanoma - and the company's strategy ahead

Dr. Zocca describes the results of the trial, which showed a 19.4 months vs. 11.0 months mPFS benefit versus pembro alone, but narrowly missed statistical significance. She shares her take on the totality of the data and discusses the road ahead, including a Q3 meeting the company will have with FDA.